FibroBiologics announces IND-enabling updates from psoriasis research program

FibroBiologics (FBLG) announced positive IND-enabling updates from its psoriasis research program demonstrating the potential of human dermal fibroblast, HDF, spheroids as a novel therapeutic approach for chronic-relapse psoriasis. The company is continuing to expand its research, including exploring repeated dosing regimens, systemic and local cytokine profiling, and histopathological assessments of skin lesions. “In an acute psoriasis model, a single administration of HDF spheroids matched the efficacy of multiple doses of an anti-IL-23 monoclonal antibody. Now, in a chronic-relapse model, that same single treatment has been shown to significantly reduce disease recurrence,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics.